Tu1670 USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN POPULATIONS WITH NASH OR AT RISK OF NASH IN US CLINICAL PRACTICE